Philips Receives FDA 510(k) Clearance for Advanced Image-Guided Navigation Technology in Prostate Cancer Care

Reuters

07-23

Philips Receives FDA 510(k) Clearance for Advanced Image-Guided Navigation Technology in Prostate Cancer Care

Koninklijke Philips NV has announced a significant advancement in prostate cancer care with the FDA 510(k) clearance for its latest image-guided navigation technology, Philips UroNav. This approval marks a major step in supporting prostate cancer diagnosis by offering clinicians more precise guidance, thereby enhancing patient care. The upgraded UroNav system integrates pre-procedural MRI with real-time ultrasound imaging, providing a dynamic and comprehensive view of the targeted area for minimally invasive procedures. Additionally, it includes a new advanced annotation workflow aimed at improving the accuracy of focal therapy procedures. This development is part of Philips' broader effort to streamline complex workflows in prostate cancer care, equipping clinicians with the necessary tools to deliver better and more precise treatment options.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Royal Philips NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001119272-en) on July 23, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2553324356"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2553324356\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2553324356?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-23 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2553324356","market":"nz","top_or_hot":-1,"title":"Philips Receives FDA 510(k) Clearance for Advanced Image-Guided Navigation Technology in Prostate Cancer Care","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Philips Receives FDA 510(k) Clearance for Advanced Image-Guided Navigation Technology in Prostate Cancer Care\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Koninklijke Philips NV has announced a significant advancement in prostate cancer care with the FDA 510(k) clearance for its latest image-guided navigation technology, Philips UroNav. This approval marks a major step in supporting prostate cancer diagnosis by offering clinicians more precise guidance, thereby enhancing patient care. The upgraded UroNav system integrates pre-procedural MRI with real-time ultrasound imaging, providing a dynamic and comprehensive view of the targeted area for minimally invasive procedures. Additionally, it includes a new advanced annotation workflow aimed at improving the accuracy of focal therapy procedures. This development is part of Philips' broader effort to streamline complex workflows in prostate cancer care, equipping clinicians with the necessary tools to deliver better and more precise treatment options.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Royal Philips NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001119272-en) on July 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Philips Receives FDA 510(k) Clearance for Advanced Image-Guided Navigation Technology in Prostate Cancer Care</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPhilips Receives FDA 510(k) Clearance for Advanced Image-Guided Navigation Technology in Prostate Cancer Care\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-07-23 21:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Philips Receives FDA 510(k) Clearance for Advanced Image-Guided Navigation Technology in Prostate Cancer Care\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Koninklijke Philips NV has announced a significant advancement in prostate cancer care with the FDA 510(k) clearance for its latest image-guided navigation technology, Philips UroNav. This approval marks a major step in supporting prostate cancer diagnosis by offering clinicians more precise guidance, thereby enhancing patient care. The upgraded UroNav system integrates pre-procedural MRI with real-time ultrasound imaging, providing a dynamic and comprehensive view of the targeted area for minimally invasive procedures. Additionally, it includes a new advanced annotation workflow aimed at improving the accuracy of focal therapy procedures. This development is part of Philips' broader effort to streamline complex workflows in prostate cancer care, equipping clinicians with the necessary tools to deliver better and more precise treatment options.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Royal Philips NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001119272-en) on July 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4112","symbol_name":"金融交易所和數據","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250723:nNDL82sn9P:1","article_id":"2553324356","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2553324356","pubTimestamp":1753275628,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Koninklijke Philips NV has announced a significant advancement in prostate cancer care with the FDA 510 clearance for its latest image-guided navigation technology, Philips UroNav. This approval marks a major step in supporting prostate cancer diagnosis by offering clinicians more precise guidance, thereby enhancing patient care. The upgraded UroNav system integrates pre-procedural MRI with real-time ultrasound imaging, providing a dynamic and comprehensive view of the targeted area for minimally invasive procedures. Additionally, it includes a new advanced annotation workflow aimed at improving the accuracy of focal therapy procedures. This development is part of Philips' broader effort to streamline complex workflows in prostate cancer care, equipping clinicians with the necessary tools to deliver better and more precise treatment options.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate an","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4112":"金融交易所和数据","BK4585":"ETF&股票定投概念","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4588":"碎股","NDAQ":"纳斯达克OMX交易所","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC"},"translate_title":"飞利浦获得FDA 510(k)许可，用于前列腺癌护理的先进图像引导导航技术","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9},"content_text":"Philips Receives FDA 510(k) Clearance for Advanced Image-Guided Navigation Technology in Prostate Cancer Care\n    \n\n        Koninklijke Philips NV has announced a significant advancement in prostate cancer care with the FDA 510(k) clearance for its latest image-guided navigation technology, Philips UroNav. This approval marks a major step in supporting prostate cancer diagnosis by offering clinicians more precise guidance, thereby enhancing patient care. The upgraded UroNav system integrates pre-procedural MRI with real-time ultrasound imaging, providing a dynamic and comprehensive view of the targeted area for minimally invasive procedures. Additionally, it includes a new advanced annotation workflow aimed at improving the accuracy of focal therapy procedures. This development is part of Philips' broader effort to streamline complex workflows in prostate cancer care, equipping clinicians with the necessary tools to deliver better and more precise treatment options.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Royal Philips NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001119272-en) on July 23, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}